RT Journal Article
SR Electronic
T1 Spike protein multiorgan tropism suppressed by antibodies targeting SARS-CoV-2
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2021.07.30.454520
DO 10.1101/2021.07.30.454520
A1 Molly Brady
A1 Abigail Combs
A1 Chethana Venkatraman
A1 Alexander Solorzano
A1 Angelique Johnson
A1 Conor McQuaid
A1 Akib Rahman
A1 Hannah Leyva
A1 Wing-Chi Edmund Kwok
A1 Ronald W Wood
A1 Rashid Deane
YR 2021
UL http://biorxiv.org/content/early/2021/08/01/2021.07.30.454520.abstract
AB While there is clinical evidence of severe acute respiratory syndrome coronavirus 2 multiorgan tropism in severely infected coronavirus 19 patients, it’s unclear if there is differential multiorgan biodistribution and organ uptake in healthy young individuals, a group that usually has asymptomatic to moderate coronavirus 19 symptoms. In addition, for antibody therapies and vaccines that target the spike protein, it’s unclear if these reduce severe acute respiratory syndrome coronavirus 2 or spike protein multiorgan tropism equally. We used fluorescently labeled spike protein near infrared fluorescence to study viral behavior, using an in vivo dynamic imaging system, in young mice. We found a spike protein body-wide biodistribution followed by a slow regional elimination, except for the liver, which showed an accumulation. Spike protein uptake was highest for the lungs, and this was followed by kidney, heart and liver, but, unlike the choroid plexus, it was not detected in the brain parenchyma or cerebrospinal fluid. Thus, the brain vascular barriers were effective in restricting the entry of spike protein into brain parenchyma in young healthy mice. While both anti-angiotensin converting enzyme 2 and anti-spike protein antibodies suppressed spike protein biodistribution and organ uptake, anti-spike protein antibody was more effective. By extension, our data support the efficacy of these antibodies on severe acute respiratory syndrome coronavirus 2 biodistribution kinetics and multiorgan tropism that could determine coronavirus 19 organ-specific outcomes.Competing Interest StatementThe authors have declared no competing interest.